FDA Approves Enhertu for HR+/HER2-low Breast Cancer: Key Trial Results & Insights Breast 3 Mins Read FDA Approves Enhertu for HR-Positive, HER2-Low and HER2-Ultralow Breast Cancer: A New Milestone in TreatmentPublished: February 20, 2025On January 27,…
FDA Approves Adcetris / brentuximab vedotin + lenalidomide & rituximab in relapsed or refractory LBCL: Could This Change Standard Care? Lymphoma 2 Mins Read Date: February 12, 2025FDA Approves Adcetris OverviewThe FDA has approved a new combination therapy for adults with relapsed or refractory…
